Change of Nominated Adviser

RNS Number : 8034B

AorTech International PLC

23 April 2012

 



AorTech International plc

("AorTech")

Change of Nominated Adviser

The directors of AorTech are pleased to announce the appointment of finnCap Limited as Nominated Adviser and Broker with immediate effect.

For further information please contact:

AorTech International plc

Frank Maguire, Chief Executive Officer

Tel: + 1 801 201 4336

Sarah Price, Media Relations

Tel: + 1 801 649 4163

e-mail [e-mail]

Stuart Andrews/Rose Herbert

finnCap

Tel: [phone]

About AorTech:

AorTech develops and manufactures biostable, implantable polymers, including Elast-Eon™ and ECSil™, the world's leading long-term implantable co-polymers, as well as proprietary processing methods for various devices, including small part RIM manufacturing. With more than 3 million implants and five years of successful clinical use, AorTech polymers are currently used in cardiology, orthopaedic, urological and gastroenterological applications, including pacing leads, cardiac cannulae and stents. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

Elast-Eon™ and ECSil's™ biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. Our polymers can be processed using conventional thermoplastic extrusion and molding techniques. AorTech provides a range of materials in a variety of application-specific formulations for use in medical devices and components.

 

END

 

 

APPLLFSESVIIFIF